Research programme: anti-CD89 antibodies - CelldexAlternative Names: CDX-1189
Latest Information Update: 05 Apr 2012
At a glance
- Originator Celldex Therapeutics Inc
- Class Monoclonal antibodies
- Mechanism of Action Fc receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Kidney disorders
Most Recent Events
- 05 Apr 2012 This programme is still active